肿瘤研究与临床
腫瘤研究與臨床
종류연구여림상
CANCER RESEARCH AND CLINIC
2014年
1期
6-8,12
,共4页
郭钢%张喜平%张俊晶%祝志川%刘海鸥
郭鋼%張喜平%張俊晶%祝誌川%劉海鷗
곽강%장희평%장준정%축지천%류해구
乳腺肿瘤%肿瘤辅助疗法%治疗结果%正电子发射断层显像术%计算机体层摄影术
乳腺腫瘤%腫瘤輔助療法%治療結果%正電子髮射斷層顯像術%計算機體層攝影術
유선종류%종류보조요법%치료결과%정전자발사단층현상술%계산궤체층섭영술
Breast neoplasms%Neoadjuvant therapy%Treatment outcome%Positron-emission tomography%Computed tomography
目的 探讨PET-CT在乳腺癌新辅助化疗(NAC)效果评价中的应用,早期预测乳腺癌NAC效果.方法 选取经空芯针穿刺确诊为乳腺癌并实施NAC的20例患者,NAC前行PET-CT检查.NAC方案采用TEC方案,3周为1个化疗周期,第1周期结束后第6天再次行PET-CT检查,观察标准摄取率SUV值,比较NAC前后SUV值的变化.行PET-CT检查同时触诊乳腺癌肿块并测量其大小,判断NAC前后乳腺癌肿块大小的变化.结果 NAC前SUV值为(7.51±1.76) Bq/ml,NAC后为(4.98±1.61) Bq/ml,差异有统计学意义(t=7.916,P＜ 0.05).NAC前肿瘤病灶最大径为(9.62土4.38)cm,NAC后为(8.89±4.08) cm,差异无统计学意义(t=2.154,P＜0.05).NAC前后SUV值的变化与病理MP分级有高度相关性(r=0.725,P＜ 0.001).NAC前后肿瘤病灶最大径缩小率与病理MP分级无相关性(r=0.026,P=0.884).结论 PET-CT可在乳腺癌NAC后、较临床疗效评价更早、更准确地鉴别出NAC有效的病例,从而避免对NAC无效者的过度治疗,支持有效者继续化疗.
目的 探討PET-CT在乳腺癌新輔助化療(NAC)效果評價中的應用,早期預測乳腺癌NAC效果.方法 選取經空芯針穿刺確診為乳腺癌併實施NAC的20例患者,NAC前行PET-CT檢查.NAC方案採用TEC方案,3週為1箇化療週期,第1週期結束後第6天再次行PET-CT檢查,觀察標準攝取率SUV值,比較NAC前後SUV值的變化.行PET-CT檢查同時觸診乳腺癌腫塊併測量其大小,判斷NAC前後乳腺癌腫塊大小的變化.結果 NAC前SUV值為(7.51±1.76) Bq/ml,NAC後為(4.98±1.61) Bq/ml,差異有統計學意義(t=7.916,P＜ 0.05).NAC前腫瘤病竈最大徑為(9.62土4.38)cm,NAC後為(8.89±4.08) cm,差異無統計學意義(t=2.154,P＜0.05).NAC前後SUV值的變化與病理MP分級有高度相關性(r=0.725,P＜ 0.001).NAC前後腫瘤病竈最大徑縮小率與病理MP分級無相關性(r=0.026,P=0.884).結論 PET-CT可在乳腺癌NAC後、較臨床療效評價更早、更準確地鑒彆齣NAC有效的病例,從而避免對NAC無效者的過度治療,支持有效者繼續化療.
목적 탐토PET-CT재유선암신보조화료(NAC)효과평개중적응용,조기예측유선암NAC효과.방법 선취경공심침천자학진위유선암병실시NAC적20례환자,NAC전행PET-CT검사.NAC방안채용TEC방안,3주위1개화료주기,제1주기결속후제6천재차행PET-CT검사,관찰표준섭취솔SUV치,비교NAC전후SUV치적변화.행PET-CT검사동시촉진유선암종괴병측량기대소,판단NAC전후유선암종괴대소적변화.결과 NAC전SUV치위(7.51±1.76) Bq/ml,NAC후위(4.98±1.61) Bq/ml,차이유통계학의의(t=7.916,P＜ 0.05).NAC전종류병조최대경위(9.62토4.38)cm,NAC후위(8.89±4.08) cm,차이무통계학의의(t=2.154,P＜0.05).NAC전후SUV치적변화여병리MP분급유고도상관성(r=0.725,P＜ 0.001).NAC전후종류병조최대경축소솔여병리MP분급무상관성(r=0.026,P=0.884).결론 PET-CT가재유선암NAC후、교림상료효평개경조、경준학지감별출NAC유효적병례,종이피면대NAC무효자적과도치료,지지유효자계속화료.
Objective To evaluate the value of PET-CT in patients with breast cancer and to determine if the PET-CT can provide additional information to predict early response to neoadjuvant chemotherapy (NAC).Methods NAC was given to 20 patients with breast cancer confirmed by biopsy puncture from September 2009 to March 2012.The PET-CT was carried out for all patients before NAC.TEC program with three weeks for one cycle was selected.After 6 days of the first cycle,the PET-CT was performed again.The changes of standard uptake value before and after the first cycle were compared.At the same time hand palpation was selected to detect the changes in tumor size before and after the first cycle of NAC.The changes of the standard uptake value and in tumor size need to refer to the pathology Miller & Payne classification methods to evaluate the efficacy of the NAC.Results The SUV were (7.51±1.76) Bq/ml and (4.98±1.61) Bq/ml before and after chemotherapy (t =7.916,P ＜ 0.05) the maximum tumor diameters were (9.62±4.38) cm and (8.89±4.08) cm before and after NAC (t =2.154,P＞ 0.05).SUV had highly correlated with pathological MP classification (r =0.725,P =0.000); while for the tumor size there was no significant change (r =0.026,P =0.824).Conclusion PET-CT can predict the efficacy earlier and is more accurate than clinical efficacy standard for the NAC.
